拉米夫定联合安络化纤丸治疗乙肝肝硬化效果探讨

The effect of lamivudine combined with the treatment of hepatitis B virus in the treatment of liver cirrhosis

目的对拉米夫定联合安络化纤丸治疗乙肝肝硬化效果进行分析。方法随机选取在我院2013年7月—2015年6月治疗的乙肝肝硬化患者86例,依据治疗方法分组,甲组43例,给予拉米夫定治疗;乙组患者43例,给予拉米夫定联合安络化纤丸治疗,对两组治疗效果进行对比分析。结果乙组患者的总体临床效果、停药后复发比例、症状缓解时间等明显高于甲组患者,(P<0.05)。患者均未发生药物引起重症过敏反应及严重不良反应。结论乙肝肝硬化患者给予拉米夫定治疗基础上联合安络化纤丸治疗能够有效提高患者的总体临床治疗效果、减少停药后复发比例、无重症不良反应和药物过敏发生,联合用药治疗效果好,安全性高。

Objective： To analyze the effect of lamivudine combined with the treatment of hepatitis B liver cirrhosis.Methods： Treated in my hospital from July 2013 and 2015 June 86 cases of patients with liver cirrhosis were randomly selected,according to the treatment group,the division of 43 cases,giving lamivudine therapy; 43 cases of patients of group B were given lamivudine joint Anluo Huaxian Wan treatment,contrast and analysis of the therapeutic effect of the two groups.Results： The overall clinical efficacy of patients in group B,after stopping the medicine recurrence ratio and symptom remission time was significantly higher than that in patients with first division,（ P〈0. 05）. No serious adverse reactions and serious adverse reactions occurred in patients with no drug. Conclusion： Patients with hepatitis B cirrhosis given lamivudine treatment on the basis of joint security Anluo Huaxian Wan treatment can effectively improve the clinical effect of general treatment of patients,reduce the withdrawal relapse rate after,no severe adverse reactions and drug allergy,drug combination therapy,safety.